Is Tivic Health Systems, Inc. overvalued or undervalued?

As of 14 November 2024, Tivic Health Systems, Inc. has seen its valuation grade change from risky to does not qualify, indicating a deterioration in its investment appeal. The company is currently assessed as overvalued given its financial metrics. Key ratios include a Price to Book Value of 1.10, an EV to EBIT of -0.47, and an EV to EBITDA of -0.50, all suggesting significant operational challenges. In comparison to its peers, Tivic Health's valuation metrics are concerning. For instance, Nexalin Technology, Inc. has an EV to EBITDA of -2.0124, while Cardio Diagnostics Holdings, Inc. shows an EV to EBITDA of 0.5065, highlighting that Tivic Health is underperforming relative to some competitors. The company's negative ROCE of -240.22% and ROE of -186.96% further reinforce the notion that it is overvalued in the current market context.